Phase 2 Lymphoma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• A tissue biopsy has confirmed a diagnosis of Diffuse Large B-Cell Lymphoma (DLBCL) according to World Health Organization classification (not including primary central nervous system lymphoma or lymphoma related to HIV).
• Tumour lesions are visible and measurable on a PET/CT scan.
• Life expectancy is estimated to be more than 3 months.
• People who received a full course of first-line lymphoma treatment and either did not respond within 90 days of the last dose, or whose disease came back after that treatment, and who are not currently receiving lymphoma treatment (at least 2 weeks must have passed since the last lymphoma therapy).
• Age is between 18 and 75 years old (inclusive), any gender.
• Able to carry out basic daily activities with minimal limitations, as measured by a standard performance scale (ECOG score of 0–2).
• Blood test results taken within 7 days before starting treatment show that major organs are functioning adequately, including: sufficient white blood cell and platelet counts; liver function within acceptable limits; kidney function within acceptable limits; and no significant heart problems.
• People of reproductive age must agree to use two reliable methods of contraception at the same time throughout the trial (confirm with trial site for full details), even if there is a history of infertility and unless a hysterectomy has been performed.
• Men who are able to father children must agree to use a condom during any sexual contact with a person who could become pregnant, both during the trial and for 28 days after stopping the study drug, even if a vasectomy has been performed.
• Participants (or their legal guardian and an impartial witness) must sign an informed consent form, showing they understand the study and agree to take part, receive treatment, and attend follow-up visits.

Who may not be able to join:

• Women who are pregnant or breastfeeding (those who are breastfeeding must agree to stop before taking the study drug).
• People with a known active Hepatitis B or Hepatitis C infection, HIV, or any other inherited or acquired immune deficiency condition.
• People who have had a blood clot in a deep vein (DVT) or a clot in the lungs (pulmonary embolism) within the past 12 months.
• People whose bone marrow is not producing enough blood cells (unless the low counts are thought to be directly caused by lymphoma in the bone marrow).
• People with significant heart disease, including unstable chest pain, a heart attack in the 6 months before joining, moderate-to-severe heart failure, or reduced pumping function of the heart.
• People whose lymphoma has spread to the central nervous system (brain or spinal cord).
• People with a known allergy to any ingredient in the study drug.
• People who had a significant surgical procedure (grade II or above) within 3 weeks before starting the trial.
• People who have previously received an organ transplant.
• People who have been diagnosed with, or are currently being treated for, a cancer other than lymphoma — unless the other cancer has been fully treated with no signs of active disease for 5 or more years, or it was a skin basal cell carcinoma or cervical carcinoma in situ that was fully treated with no remaining signs of disease.
• People with a serious active infection.
• People with substance use issues, or medical, psychological, or social circumstances that the research team considers could interfere with safe participation in the trial or with assessing the results.

Important: Always verify eligibility with the trial site directly before applying.